Preclinical Anti-Tumor Efficacy of a Novel Anti-c-Kit Antibody Drug Conjugate, NN3201, in c-Kit Positive Tumors
1. 系统已在2025-09-18 14:46:42对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
C Kim, J Park, JO Kim, HJ Ko, JG Cho…
Molecular Cancer …, 2025
aacrjournals.org
Overexpression and gain-of-function mutations of c-Kit have been implicated in cancers including gastrointestinal stromal tumors (GIST), small cell lung cancer (SCLC), acute myeloid leukemia, and systematic mastocytosis. In clinics, small molecule c-Kit inhibitors often result in secondary c-Kit mutations or are ineffective despite c-Kit overexpression. We developed NN3201, a novel c-Kit targeting antibody-drug conjugate (ADC), via rational design to evaluate its anticancer activity in c-Kit-positive tumors, and preclinical …
